Evidence map›Paper›PMID 34091990›Full record

ArticleCancer science2021

Heterogenous expression of endoglin marks advanced renal cancer with distinct tumor microenvironment fitness.

Yusaku Momoi, Jun Nishida, Kosuke Miyakuni, Masafumi Kuroda, Shimpei I Kubota, Kohei Miyazono, Shogo Ehata

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yusaku MomoiDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.
Jun NishidaDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0001-5098-9361
Kosuke MiyakuniDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.
Masafumi KurodaInternational Research Center for Neurointelligence (WPI-IRCN), UTIAS, The University of Tokyo, Bunkyo-ku, Japan.
Shimpei I KubotaDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0003-3188-3988
Kohei MiyazonoDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0001-7341-0172
Shogo EhataDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0002-6740-9391
The University of Tokyo · JPBunkyo University · JP

Funding

Japan Society for the Promotion of Science (JSPS), KAKENHI Grant-in-Aid for Scientific Research (C) 19K07684Princess Takamatsu Cancer Research Fundthe Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, KAKENHI Grant-in-Aid for Scientific Research on Innovative Area on Integrated Analysis and Regulation of Cellular Diversity 17H06326
6 · The paper itself

Abstract

Intratumoral heterogeneity, including in clear cell renal cell carcinoma, is a potential cause of drug resistance and metastatic cancer progression. We specified the heterogeneous population marked by endoglin (also known as CD105) in a preclinical model of clear cell renal cell carcinoma progression. Highly malignant derivatives of human clear cell renal cell carcinoma OS-RC-2 cells were established as OS5Ks by serial orthotopic inoculation in our previous study. Expression of both ENG (encoding endoglin) mRNA and protein were heterogeneously upregulated in OS5Ks, and the endoglin-positive (ENG

Indexed as

Up-RegulationAnimalsCarcinoma, Renal CellCell Line, TumorCell ProliferationEndoglinGene Expression Regulation, NeoplasticGenetic HeterogeneityHumansKidney NeoplasmsMaleMiceNeoplasm TransplantationNeoplastic Stem CellsTumor MicroenvironmentEndoglinENG protein, humancancer stem cellendoglinrenal cancertumor heterogeneitytumor microenvironment

Identifiers

PMID34091990
PMCPMC8353946
OpenAlexW3169620925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.